A new European-wide observational study to prospectively gather data on patients treated with irinotecan-loaded microspheres has been launched by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). The CIRSE Registry for Lifepearl Microspheres (CIREL) will begin early in 2016.
The CIRSE Registry for Lifepearl Microspheres (CIREL) will prospectively observe the administration of irinotecan-eluting microspheres, a newly CE-approved transcatheter chemo-embolisation (TACE) system and marks the second major observational study led solely by CIRSE. The primary endpoint is to map the exact indications which the device is being used for and at which stage in treatment it is being applied.
Supported by a grant provided by Terumo Europe, the study will be overseen by a multidisciplinary Steering Committee made up of renowned experts including Chairmen Profs. Philippe Pereira (Director Clinic of Radiology, Minimally Invasive Therapies and Nuclear Medicine Heilbronn) and Julien Taieb (Gastroenterology, Hopital Européen George Pompidou).
Enthused by the endeavour, Prof. Pereira remarked: „This observational study will not only provide us with robust, multi-centre data on the precise use and efficacy and safety profiles of this particular device but also give some insight into how TACE can fit into the established lines of standard clinical practice in Europe."
CIRSE is a non-profit, educational and scientific association aiming to improve patient care through the support of teaching, science, research and clinical practice in the field of minimally invasiveimage-guided medicine (interventional radiology). CIREL is the second observational study sponsored exclusively by CIRSE.
For further information on LifePearl drug elutable microspheres click here.